References
- Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., et al. (2002) "Pretreatment cytogenetics abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)", Blood, 100, 4325–4336.
- Delaunay, J., Vey, N., Leblanc, T., Fenaux, P., Rigal-Huguet, F., Witz, F., et al. (2003) "Prognosis of inv(16/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup", Blood, 102, 462–469.
- Vardiman, J., Mnizek, K., Anastasi, J., Kolitz, J., Carroll, A.J., Caligiuiri, M., et al. for the Cancer and Leukemia Group B (2000) "Morphology and CBFB/MYHI 1 transcripts in AML (CALGB study 9621)", Lab. Invest., 80, 165A.
- Rozman, M., Navarro, J.-T., Domingo, A., Ayats, R., Vallespi, T., Gallart, M., et al. (2002) "Morphologic characterization of acute myeloid leukemia with cytogenetic or molecular evidence of t(8;21), t(15;17), inv(I6) and 11q23 abnormalities", Haematologica, 87, 886 — 887.
- Mnizek, K., Heinonen, K. and Bloomfield, C.D. (2001) "Clinical importance of cytogenetics in acute myeloid leukaemia", Best Practice & Research Clinical Haematology, 14, 19–47.
- Wong, K.F. and Kwong, Y.L. (1999) "Trisomy 22 in acute myeloid leukemia: a marker for myeloid leukemia with monocytic features and cytogenetically cryptic inversion 16", Cancer Genet. Cytogenet., 109, 131 — 133.